A groundbreaking study led by researchers at the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai has fundamentally shifted the scientific understanding of Phelan-McDermid syndrome (PMS). Published in the journal Autism Research, the comprehensive investigation indicates that this rare genetic disorder occurs in approximately 1 in every 7,300 individuals. This new prevalence figure suggests that the condition is significantly more common than earlier estimates had acknowledged, pointing to a vast population of undiagnosed individuals—potentially exceeding 45,000 people in the United States alone.
The findings arrive at a critical juncture in neurology and pediatric genetics. As biotechnology firms and academic institutions advance targeted, precision-medicine therapies into human clinical trials, the imperative to identify every living patient has transitioned from a purely diagnostic exercise into an urgent medical and ethical necessity. The study was supported by advocacy and industry partners including CureSHANK and Neuren Pharmaceuticals, underscoring a unified effort across the medical ecosystem to bridge the gap between genetic discovery and clinical intervention.
Understanding Phelan-McDermid Syndrome and the SHANK3 Gene
Phelan-McDermid syndrome is a complex genetic disorder primarily driven by a deletion or mutation involving the SHANK3 gene located on the terminal end of chromosome 22 (specifically band 22q13.3). The SHANK3 gene plays a monumental role in human neurobiology, encoding a master scaffolding protein found in the postsynaptic density of excitatory synapses in the brain. This protein is essential for proper neuronal communication, synaptic plasticity, and the structural integrity of neural networks.
When the SHANK3 gene is mutated or deleted, the resulting synaptic dysfunction reverberates throughout the central nervous system. Clinically, this manifests as a broad spectrum of medical, intellectual, and behavioral challenges. Affected individuals frequently experience global developmental delay, severe speech impairments, hypotonia (low muscle tone), motor deficits, epilepsy, and gastrointestinal issues. Furthermore, a vast majority of individuals diagnosed with PMS also meet the diagnostic criteria for autism spectrum disorder (ASD). In fact, genetic alterations affecting the SHANK3 gene are currently understood to account for up to one percent of all autism spectrum disorder cases worldwide, making it one of the most common single-gene causes of autism.
Despite the profound impact of these symptoms, obtaining a definitive diagnosis has historically been difficult for families navigating the healthcare system. The clinical presentation of PMS overlaps heavily with other neurodevelopmental disorders, meaning that physical examination and standard behavioral evaluations are rarely sufficient to pinpoint the root genetic cause. Only specialized genetic testing can confirm a diagnosis of Phelan-McDermid syndrome, leaving countless patients obscured behind broader diagnostic labels like idiopathic autism or intellectual disability.
Methodology: Uncovering the True Prevalence Through Massive Data Analysis
To arrive at their revised prevalence estimate of 13.7 cases per 100,000 individuals—translating to roughly 1 in 7,300—the Mount Sinai research team undertook a massive data-aggregation effort. Recognizing that previous epidemiological models may have been skewed by underreporting and limited testing access, the investigators designed a study that pulled from nearly 180,000 genetic records of individuals diagnosed with autism spectrum disorder.
The research team synthesized data collected across ten distinct and rigorous sources. This cooperative network included prominent commercial genetic testing laboratories such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale academic research initiatives like the SPARK research study (Simons Simplex Collection and Simons Foundation Powering Autism Research for Knowledge) and the Autism Sequencing Consortium. Data from several major tertiary pediatric medical centers were also integrated into the final analysis.
Analyzing this unprecedented volume of genomic data allowed the researchers to look past the limitations of individual clinics or localized cohorts. However, simply counting positive test results in an autism registry is not enough to determine true population prevalence, as many individuals with PMS do not present with classic autism, and many individuals with autism never receive comprehensive genetic testing. To account for these confounding variables, the research team adjusted their models to factor in undiagnosed cases within the broader population, technological limitations inherent in older or targeted genetic panels, and individuals who live with Phelan-McDermid syndrome but fall outside the diagnostic boundaries of autism spectrum disorder.
The resulting calculation—13.7 per 100,000—represents a substantial upward revision of older medical literature, which often categorized PMS as an ultra-rare condition with vague, lower estimates. By scaling this proportion to the general population, the study reveals that tens of thousands of children and adults currently walking through life with unexplained developmental delays may actually have Phelan-McDermid syndrome.
The Diagnostic Bottleneck: Why Thousands Remain Uncounted
The profound discrepancy between the number of officially diagnosed PMS cases and the newly calculated prevalence figures points to deep systemic shortcomings within modern healthcare infrastructure. Tess Levy, MSc, an assistant professor of psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the study, highlighted the primary drivers of this diagnostic gap.
"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. Even when clinicians suspect a genetic etiology, families routinely encounter administrative and financial roadblocks. Insurance providers frequently deny coverage for comprehensive chromosomal microarray analysis or full exome sequencing, deeming them elective or non-essential for daily clinical management. Furthermore, many patients receive older, lower-resolution genetic tests that fail to interrogate the 22q13 region or lack the sensitivity to detect nuanced mutations within the SHANK3 gene itself.
This diagnostic bottleneck leaves families in an informational vacuum. Without a specific genetic diagnosis, patients are often prescribed generalized therapies that fail to address the underlying molecular pathology of their condition. They miss out on condition-specific medical surveillance—such as regular renal and cardiac evaluations, which are often recommended for individuals with chromosomal deletions—and remain isolated from peer support networks tailored to the specific challenges of Phelan-McDermid syndrome.
The Imperative of Universal Genetic Testing
In response to these findings, the leadership at the Seaver Autism Center is renewing its advocacy for a paradigm shift in pediatric neurology and developmental psychiatry. The researchers argue that genetic investigation should no longer be treated as a secondary or last-resort option reserved for atypical presentations. Instead, it should become a foundational pillar of clinical care for every child presenting with neurodevelopmental concerns.
"We recommend that every child with autism undergo genetic testing, because knowledge is power," stated Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the paper. Dr. Buxbaum emphasized that uncovering the precise molecular architecture of a patient’s condition does more than satisfy intellectual curiosity; it transforms the trajectory of clinical research. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
This sentiment is echoed by industry stakeholders who see the epidemiological data as a call to action. Dr. Rachel Groth, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals—a company actively developing targeted therapeutics—stressed that patient identification is now an ethical necessity.
"Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth noted. "Patients cannot benefit from these advances if they never receive a diagnosis."
A New Era of Clinical Trials and Precision Medicine
The publication of this prevalence study coincides with an unprecedented wave of scientific optimism regarding therapeutic interventions for Phelan-McDermid syndrome. For decades, the medical management of PMS was strictly palliative, focusing on physical therapy, speech therapy, and behavioral interventions designed to help patients cope with developmental delays and communication barriers. While these supportive therapies remain vital, they do nothing to alter the underlying biological mechanisms driven by SHANK3 deficiency.
Today, however, a growing pipeline of clinical trials is testing precision medicine approaches explicitly designed to target the neurobiological pathways disrupted in PMS. Because the SHANK3 protein is intimately connected to synaptic signaling and neurotransmitter balance, researchers are exploring pharmacological agents that can restore synaptic function, enhance neural plasticity, or compensate for deficient signaling pathways in the brain.
For families and clinicians, obtaining a genetic diagnosis is no longer merely an academic exercise yielding a static label. It serves as a golden key capable of unlocking specialized medical oversight, connecting families to dedicated patient advocacy networks, and providing direct eligibility for cutting-edge clinical trials that could fundamentally alter the course of the disease.
Geraldine Bliss, Board Chair of CureSHANK—a patient-advocacy organization dedicated to finding a cure for the syndrome—highlighted the emotional and practical weight of the new study for affected families. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
Broader Implications: The "Think Genetic First" Movement
The wider medical and public health implications of the Mount Sinai study extend far beyond the specialized field of rare disease research. They reinforce ongoing global initiatives aimed at modernizing clinical diagnostics. CureSHANK, alongside international partners, is actively championing awareness campaigns such as Start Genetic, which encourages physicians, pediatricians, healthcare systems, and families to adopt a "think genetic first" mindset when evaluating children with developmental delays or autism spectrum disorders.
Public health analysts point out that as precision medicine matures, the bottleneck in healthcare delivery is shifting from scientific discovery to patient identification. Drug developers can successfully engineer molecules that target specific genetic mutations, but those therapies cannot reach patients who remain invisible to the healthcare system. By proving that Phelan-McDermid syndrome is nearly twice as prevalent as previously understood, this study provides the empirical justification needed for healthcare systems, insurers, and policymakers to streamline access to genetic testing.
Ultimately, the collaborative work by Mount Sinai, CureSHANK, Neuren Pharmaceuticals, and their contributing testing laboratories establishes a new benchmark for rare disease epidemiology. As clinical trials progress and diagnostic barriers slowly begin to erode, the tens of thousands of individuals currently living in the shadows of undiagnosed neurodevelopmental conditions may finally find the clarity, community, and targeted treatments they have long deserved.
